[HTML][HTML] Strategies for multivessel revascularization in patients with diabetes
…, JE Sousa, J Rankin, B Bhargava… - New England journal …, 2012 - Mass Medical Soc
Background In some randomized trials comparing revascularization strategies for patients
with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than …
with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than …
[HTML][HTML] Initial invasive or conservative strategy for stable coronary disease
…, AP Maggioni, HD White, B Bhargava… - … England Journal of …, 2020 - Mass Medical Soc
Background Among patients with stable coronary disease and moderate or severe ischemia,
whether clinical outcomes are better in those who receive an invasive intervention plus …
whether clinical outcomes are better in those who receive an invasive intervention plus …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
Background To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month …
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
…, PW Serruys, AJ Lansky, P Fitzgerald, B Bhargava… - Circulation, 2000 - Am Heart Assoc
Background—Treatment of in-stent restenosis presents a critical limitation of intracoronary
stent implantation. Ionizing radiation has been shown to decrease neointimal formation within …
stent implantation. Ionizing radiation has been shown to decrease neointimal formation within …
Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India
…, S Panda, S Mande, R Swarup, B Bhargava… - BioRxiv, 2021 - biorxiv.org
As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
expands, genomic epidemiology and whole genome sequencing are being constantly used to …
expands, genomic epidemiology and whole genome sequencing are being constantly used to …
Neutralization of variant under investigation B. 1.617. 1 with sera of BBV152 vaccinees
…, AM Shete, S Panda, B Bhargava… - Clinical Infectious …, 2022 - academic.oup.com
To the Editor—The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants in places where the virus is uncontained poses a global threat from the …
variants in places where the virus is uncontained poses a global threat from the …
Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020
…, DCS Reddy, B Bhargava - Indian Journal of …, 2020 - journals.lww.com
Methods: From May 11 to June 4, 2020, a randomly sampled, community-based survey was
conducted in 700 villages/wards, selected from the 70 districts of the 21 States of India, …
conducted in 700 villages/wards, selected from the 70 districts of the 21 States of India, …
SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: findings from the second nationwide household serosurvey
…, S Panda, DCS Reddy, B Bhargava… - The Lancet Global …, 2021 - thelancet.com
Background The first national severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from …
serosurvey in India, done in May–June, 2020, among adults aged 18 years or older from …
